Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide
Novo Nordisk A/S
Summary
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: \- On maintenance treatment with either liraglutide 3.0 milligram (mg) for at least 5 days, oral semaglutide 25 mg for at least 5 weeks or semaglutide 2.4 mg for at least 5 weeks prior to screening. Exclusion Criteria: * Previous dosing in this study. * Previous rescreening for this study. * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method * Current participation (i.e., signed informed consent) in any other interventional clinical study. * Exposure to investigational medicinal…
Interventions
- DrugLiraglutide
Participants will receive liraglutide subcutaneously.
- DrugOral Semaglutide
Participants will receive semaglutide orally.
- DrugSemaglutide
Participants will receive semaglutide subcutaneously.
Location
- Altasciences Clinical LA, Inc.Cypress, California